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Vitiligo is an autoimmune disease in which depigmented skin results from destruction of 45 
melanocytes1, with epidemiologic association with other autoimmune diseases2. In 46 
previous linkage and genome-wide association studies (GWAS1, GWAS2), we identified 47 
27 vitiligo susceptibility loci in patients of European (EUR) ancestry. We carried out a 48 
third GWAS (GWAS3) in EUR subjects, with augmented GWAS1 and GWAS2 controls, 49 
genome-wide imputation, and meta-analysis of all three GWAS, followed by an 50 
independent replication. The combined analyses, with 4,680 cases and 39,586 controls, 51 
identified 23 new loci and 7 suggestive loci, most encoding immune and apoptotic 52 
regulators, some also associated with other autoimmune diseases, as well as several 53 
melanocyte regulators. Bioinformatic analyses indicate a predominance of causal 54 
regulatory variation, some corresponding to eQTL at these loci. Together, the identified 55 
genes provide a framework for vitiligo genetic architecture and pathobiology, highlight 56 
relationships to other autoimmune diseases and melanoma, and offer potential targets 57 
for treatment. 58 
 59 
In previous genome-wide linkage and association studies, we identified 27 vitiligo susceptibility loci3-6 in 60 
EUR subjects, principally encoding immunoregulatory proteins, many of which are associated with other 61 
autoimmune diseases7. Several other vitiligo-associated genes encode melanocyte components that 62 
regulate normal pigmentary variation8 and in some cases are major vitiligo autoimmune antigens, with an 63 
inverse association of variation at these loci with vitiligo versus malignant melanoma4,6. To detect 64 
additional vitiligo-associations with lower odds ratios (ORs), as well as uncommon risk alleles with 65 
higher ORs, we conducted a third GWAS (GWAS3) of EUR subjects. We augmented the number of 66 
population controls in our previous GWAS1 and GWAS2 and performed genome-wide imputation of all 67 
three EUR vitiligo GWAS. After quality control procedures, the augmented studies included 1,381 cases 68 
and 14,518 controls (GWAS1), 413 cases and 5,209 controls (GWAS2), and 1,059 cases and 17,678 69 
controls (GWAS3), with genomic inflation factors 1.068, 1.059, and 1.013, respectively. We performed a 70 
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fixed-effects meta-analysis of the three GWAS datasets for 8,966,411 markers (GWAS123; Online 71 
Methods). Replication used an additional 1,827 EUR vitiligo cases and 2,181 controls.  72 
Results for the three individual GWAS, the meta-analysis, and the replication study are presented 73 
in Table 1, Supplementary Table 1, and Fig. 1. Twenty-three new loci achieved genome-wide 74 
significance (P < 5 x 10-8) for association with vitiligo and demonstrated subsequent replication; of these, 75 
21 are completely novel (FASLG, PTPRC, PPP4R3B, BCL2L11, FARP2-STK25, UBE2E2, FBXO45-76 
NRROS, PPP3CA, IRF4, SERPINB9, CPVL, NEK6, ARID5B, a multigenic segment that includes BAD, 77 
TNFSF11, KAT2A-HSPB9-RAB5C, TNFRSF11A, SCAF1-IRF3-BCL2L12, a multigenic segment that 78 
includes ASIP, PTPN1, and IL1RAPL1), while two, CTLA4 and TICAM1, were suggestive in our previous 79 
studies. One previously significant locus, CLNK, was no longer significant (Supplementary Table 1). 80 
Another potential new locus, PVT1, exceeded genome-wide significance in the discovery meta-analysis 81 
(P = 7.74 x 10-9), but could not be successfully genotyped in the replication study and so remains 82 
uncertain. Two other loci, FLI1 and LOC101060498, exceeded genome-wide significance in the 83 
discovery meta-analysis (P = 3.76 x 10-8 and P = 3.60 x 10-11, respectively), but did not demonstrate 84 
replication. Seven additional novel loci achieved suggestive significance (P < 10-5) in the discovery meta-85 
analysis (STAT4, PPARGC1B, c7orf72, PARP12, FADS2, CBFA2T3, and a chr17 locus in the vicinity of 86 
AFMID) and gave evidence of replication, but failed to achieve genome-wide significance 87 
(Supplementary Table 1).  88 
 Together, the most significantly associated variants at the 48 loci (Table 1) identified by meta-89 
analyses of the three GWAS account for 17.4% of vitiligo heritability (h2 ~ 0.75). To assess whether 90 
additional independent variants at these loci might account for additional vitiligo heritability, we 91 
performed logistic regression conditional on the most significant SNP at each locus. Eight loci (FARP2-92 
STK25, IFIH1, IL2RA, LPP, MC1R, SLA/TG, TYR, UBASH3A) and the MHC showed evidence of 93 
additional independent associations, accounting for an additional 5.1% of vitiligo heritability, for a total 94 
of 22.5%. In general, the ORs for the 23 new confirmed loci were lower than those for loci detected 95 
previously6, 1.15 to 1.27, excepting CPVL (OR = 1.84), RALY-EIF252-ASIP-AHCY-ITCH (OR = 1.64), 96 
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and IL1RAPL1 (OR = 1.77); for these three signals the associated alleles are uncommon (minor allele 97 
frequencies 0.03, 0.07, and 0.01, respectively) and thus were not detected in the previous GWAS due to 98 
power limitations.  99 
To screen for functional relationships among proteins encoded at the 48 confirmed vitiligo-100 
associated loci, we included all genes under the association peaks at these loci in unsupervised pathway 101 
analyses using g:PROFILER9, PANTHER10, and STRING11. PANTHER and gPROFILER identified an 102 
enriched network of BioGRID interactions, most significant for the GO categories immune response, 103 
immune system process, positive regulation of response to stimulus, positive regulation of biological 104 
process, and regulation of response to stimulus. STRING identified a large potential interaction network 105 
(Fig. 2), with a predominance of proteins involved in immunoregulation, T-cell receptor repertoire, 106 
apoptosis, antigen processing and presentation, and melanocyte function. 107 
Considering proteins encoded at the 23 newly confirmed vitiligo candidate loci, at least twelve 108 
(CTLA4, TICAM1, PTPRC, FARP2, UBE2E2, NRROS, CPVL, ARID5B, PTPN1, TNFSF11, 109 
TNFRSF11A, IRF3, and perhaps also IL1RAPL1) play roles in immune regulation, and PPP3CA may 110 
regulate FOXP3 via NFATC2 and is associated with canine lupus12. Six (FASLG, BCL2L11, BCL2L12, 111 
SERPINB9, NEK6, BAD) are regulators of apoptosis, particularly involving immune cells. ASIP is a 112 
regulator of melanocyte gene expression, and IRF4 is a key transcription factor for both immune cells and 113 
melanocytes.  114 
Strikingly, several vitiligo-associated genes encode proteins that interact physically and 115 
functionally. BCL2L11 and BAD are binding partners that promote apoptosis13. CD80 binds to CTLA4 to 116 
inhibit T cell activation14. BCL2L12 binds to and neutralizes caspase 7 (CASP7)15. SERPINB9 binds to 117 
and specifically inhibits granzyme B (GZMB)16. Eos (IKZF4) binds and is an obligatory co-repressor of 118 
FOXP3 in regulatory T cells17. RANK (TNFRSF11A) binds to RANKL (TNFSF11) to regulate many 119 
aspects of immune cell function, including interactions of T cells and dendritic cells and thymic 120 
tolerization18. Agouti signaling protein (ASIP) binds to the melanocortin-1 receptor (MC1R) to down-121 
regulate production of brown-black eumelanin19. IRF4 cooperates with MITF to activate transcription of 122 
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TYR20. And the vitiligo-associated HLA-A*02:01:01:01 subtype presents peptide antigens derived from 123 
several different melanocyte proteins, including tyrosinase (TYR), OCA2, and MC1R4,6,21. Together, these 124 
relationships appear to highlight key pathways of vitiligo pathogenesis that are beginning to coalesce.  125 
An unexpected finding from vitiligo GWAS has been an inverse relationship between vitiligo and 126 
malignant melanoma risk for genes that encode melanocyte structural and regulatory proteins. TYR, 127 
OCA2, and MC1R, encode functional components of the melanocyte and are key vitiligo autoantigens. 128 
IRF4 encodes a transcription factor for melanocytes as well as lymphoid, myeloid, and dendritic cells22, 129 
controlled by alternative tissue-specific enhancers23. ASIP and PPARGC1B encode paracrine regulators of 130 
melanocyte gene expression. All six loci play important roles in normal pigmentary variation8,24, and for 131 
all six the specific SNPs associated with vitiligo risk are also associated with melanoma protection, and 132 
vice-versa25-27. The inverse genetic relationship of susceptibility to vitiligo versus melanoma suggests that 133 
vitiligo may represent enhanced immune surveillance against melanoma27,28, consistent with the threefold 134 
reduction in melanoma incidence among vitiligo patients29,30 and prolonged survival of melanoma patients 135 
who develop vitiligo during immunotherapy31.  136 
Vitiligo is epidemiologically associated with several other autoimmune diseases, including 137 
autoimmune thyroid disease, pernicious anemia, rheumatoid arthritis, adult-onset type 1 diabetes, 138 
Addison’s disease, and lupus2,32. We searched the NHGRI-EBI GWAS Catalog and PubMed for the 48 139 
genome-wide significant and 7 suggestive vitiligo susceptibility loci for associations with other 140 
autoimmune, inflammatory, and immune-related disorders. As shown in Fig. 3, of the 23 novel genome-141 
wide significant vitiligo loci, FASLG has been associated with celiac disease33 and Crohn’s disease34; 142 
PTPRC with ulcerative colitis35; BCL2L11 with primary sclerosing cholangitis36; CTLA4 with alopecia 143 
areata37, rheumatoid arthritis38, autoimmune thyroid disease39,40, myasthenia gravis41, and type 1 diabetes 144 
autoantibody production42; TNFRSF11A with myasthenia gravis41; and ARID5B with systemic lupus 145 
erythematosus43. Of the seven suggestive loci, STAT4 has been associated with Behḉet’s disease44, 146 
Sjögren’s syndrome45, and lupus46; and c7orf72 with lupus47. These concordant associations for vitiligo 147 
and other autoimmune and inflammatory diseases add to those involving previously identified vitiligo 148 
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susceptibility loci, which include RERE, PTPN22, IFIH1, CD80, LPP, BACH2, RNASET2-FGFR1OP-149 
CCR6, TG/SLA, IL2RA, CD44, a chr11q21 gene desert, IKZF4, SH2B3-ATXN2, UBASH3A, and 150 
C1QTNF64,6. Nevertheless, in most cases it remains uncertain whether apparent shared locus associations 151 
for different autoimmune diseases reflect shared or different underlying causal variants. 152 
A majority of loci associated with complex traits involve causal variants that are regulatory in 153 
nature48-52, often corresponding to apparent expression quantitative trait loci (eQTLs)52. For TYR21, 154 
GZMB53, and MC1R7, principal vitiligo risk derives from missense substitutions, whereas for OCA26 and 155 
the MHC class I54 and class II55 loci principal vitiligo risk is associated with causal variation in nearby 156 
transcriptional regulatory elements. To assess the fraction of vitiligo-associated loci for which causal 157 
variation is likely regulatory, we carried out conditional logistic regression analysis of all loci to define 158 
independent association signals, and for each signal we compiled all variants that could not be statistically 159 
distinguished. All variants were then annotated against all available ENCODE datasets for immune-160 
related and melanocyte-related cells (Supplementary Table 2). Overall, at approximately 58% of loci, 161 
the most significant variants (or statistically indistinguishable variants) are within a transcriptional 162 
regulatory element predicted by ENCODE data56,57. Only about 15% are in coding regions, several 163 
resulting in missense substitutions. To further assess the general functional categories of apparent causal 164 
variants for vitiligo, we applied stratified LD score regression51 to the GWAS meta-analysis summary 165 
statistics. As shown in Fig. 4, greatest enrichment of heritability was observed for markers in regulatory 166 
functional categories, with considerably less enrichment of markers in protein coding regions. 167 
We utilized two approaches to assess correspondence of vitiligo association signals with 168 
expression of genes in the vicinity. We used PrediXcan58 to predict expression of 11,553 genes in whole 169 
blood for each study subject and then tested association of predicted expression of each gene with vitiligo 170 
affection status. We used a Bayesian method to assess co-localization of cis eQTL signals in purified 171 
blood monocytes with the confirmed vitiligo association signals. The PrediXcan analysis found 83 genes 172 
with significant differential predicted expression in vitiligo cases versus controls after Bonferroni 173 
correction (Supplementary Table 3); of these, 75 were located within 1 Mb of one of the 48 confirmed 174 
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vitiligo susceptibility loci, demonstrating highly significant enrichment compared with locations of genes 175 
non-significant for PrediXcan (P value < 0.00001). The eQTL analysis found that 8 of the confirmed 176 
vitiligo association signals showed significant co-localization with eQTL association signals identified in 177 
purified monocytes (Supplementary Fig. 1 and Supplementary Table 4). Of the confirmed vitiligo-178 
associated genes that could be tested using both methods, 6 were significant in both analyses (CASP7, 179 
HERC2-OCA2, ZC3H7B-TEF, TICAM1, RERE, RNASET2-FGFR1OP-CCR6). For all of these except 180 
CASP7, one or more of the most associated SNPs not distinguishable by logistic regression was located 181 
within or very close to an ENCODE element likely to regulate gene expression in immune cell types, 182 
melanocytes, or both (Supplementary Table 2).  183 
Like a jigsaw puzzle, the pieces of the vitiligo pathogenome are thus beginning to fit together, 184 
revealing a complex network of immunoregulatory proteins, apoptotic regulators, and melanocyte 185 
components that mediate both autoimmune targeting of melanocytes in vitiligo and susceptibility to 186 
melanoma. For vitiligo as for other complex diseases, there is enrichment of causal variation in regions 187 
that regulate gene expression. This may bode well for identifying potential therapeutic targets, as 188 
pharmacologic modulation of dysregulated biological pathways may prove more tractable than attempting 189 
to target proteins impacted by amino acid substitutions.  190 
 191 
 192 
URLs. 1000 Genomes Project, http://www.1000genomes.org/; 1000 Genomes Project data, 193 
http://www.sph.umich.edu/csg/abecasis/MACH/download/ 1000G-2010-08.html; NHGRI-EBI GWAS 194 
Catalog, http://www.ebi.ac.uk/gwas/; NIH Database of Genotypes and Phenotypes (dbGaP), 195 
http://www.ncbi.nlm.nih.gov/gap; Online Mendelian Inheritance in Man (OMIM), 196 
http://www.ncbi.nlm.nih.gov/omim; PLINK, http://pngu.mgh.harvard.edu/purcell/plink/; STATA, 197 
http://www.stata.com; STRING database, http://string-db.org.  198 
 199 
9 
 
Accession Codes. Genotype and phenotype data for GWAS1, GWAS2, and GWAS 3 have been 200 
deposited with the NIH Database of Genotypes and Phenotypes (dbGaP) as phs000224.v1.p1, 201 
phs000224.v2.p1, and phs000224.v3.p1, respectively. 202 
 203 
ACKNOWLEDGMENTS 204 
We thank the thousands of vitiligo patients and normal control individuals around the world who 205 
participated in this study. We thank the Center for Inherited Disease Research (CIDR) for genotyping. 206 
This work utilized the Janus supercomputer, which is supported by the National Science Foundation 207 
(award number CNS-0821794), the University of Colorado Boulder, the University of Colorado Denver, 208 
and the National Center for Atmospheric Research. The Janus supercomputer is operated by the 209 
University of Colorado Boulder. This work was supported by grants R01AR045584, R01AR056292, 210 
X01HG007484, and P30AR057212 from the U.S. National Institutes of Health and by institutional 211 
research funding IUT20-46 from the Estonian Ministry of Education and Research. 212 
 213 
AUTHOR CONTRIBUTIONS 214 
Y.J., G.A. and D.Y. performed statistical analyses. J.S. managed computer databases, software, and 215 
genotype data. T.M.F., S.B., G.A., and K.M.B. managed DNA samples and contributed to experimental 216 
procedures. P.J.H. managed subject coordination. S.A.B., A.H., A.L., R.M.L., A.W., J.P.W.vdV., N.vG., 217 
J.L., D.C.B., A.T., K.E., E.H.K., D.J.G., A.P.W., S.K., E.P., K.K., M.K., M.R.W., W.T.M., A.O., S.M., 218 
R.C., M.P., N.B.S., M.S., Y.V., I.K., M.B., H.L., I.H., L.Z., and Q.-S.M. provided subject samples and 219 
phenotype information. S.A.S., P.R.F. and R.A.S. conceived, oversaw, and managed all aspects of the 220 
study. R.A.S. wrote the first draft of the manuscript. All authors contributed to the final paper. 221 
 222 
 223 
  224 
10 
 
References (Main text) 225 
1. Picardo, M. & Taïeb, A. (eds.) Vitiligo (Springer, Heidelberg & New York, 2010). 226 
2. Alkhateeb, A. et al. Epidemiology of vitiligo and associated autoimmune diseases in 227 
Caucasian probands and their families. Pigment Cell Res. 16, 208–214 (2003). 228 
3. Jin, Y. et al. NALP1 in vitiligo-associated multiple autoimmune disease. N. Engl. J. Med. 229 
356, 1216-1225 (2007). 230 
4. Jin, Y. et al. Variant of TYR and autoimmunity susceptibility loci in generalized vitiligo. N. 231 
Engl. J. Med. 362, 1686–1697 (2010). 232 
5. Jin, Y. et al. Common variants in FOXP1 are associated with generalized vitiligo. Nat. 233 
Genet. 42, 576-578 (2010). 234 
6. Jin, Y. et al. Genome-wide association study and meta-analysis identifies 13 new 235 
melanocyte-specific and immunoregulatory susceptibility loci for generalized vitiligo. Nat. 236 
Genet. 44, 676-680 (2012). 237 
7. Ricano-Ponce I & Wijmenga C. Mapping of immune-mediated disease genes. Annu. Rev. 238 
Genomics Hum. Genet. 14, 325–353 (2013). 239 
8. Liu F. et al. Genetics of skin color variation in Europeans: genome-wide association studies 240 
with functional follow-up. Hum Genet. 134, 823–835 (2015). 241 
9. Reimand, J., Arak, T. & Vilo J. g:Profiler—a web server for functional interpretation of gene 242 
lists (2011 update). Nucleic Acids Res., 39, W307-15 (2011). 243 
10. Mi, H., Poudel, S., Muruganujan, A., Casagrande, J.T. & Thomas P.D. PANTHER version 244 
10: expanded protein families and functions, and analysis tools. Nucleic. Acids. Res. 44, 245 
D336-342 (2016). 246 
11. Szklarczyk, D. et al. STRING v10: protein-protein interaction networks, integrated over the 247 
tree of life. Nucleic Acids Res. 43, D447-D452 (2015). 248 
12. Wilbe, M., et al. Multiple changes of gene expression and function reveal genomic and 249 
phenotypic complexity in SLE-like disease. PLoS Genet. 11, e1005248 (2015). 250 
11 
 
13. Wang, X., Xing, D., Liu, L. & Chen, W.R. BimL directly neutralizes Bcl-xL to promote Bax 251 
activation during UV-induced apoptosis. FEBS Lett. 583, 1873-1879 (2009). 252 
14. Linsley, P.S. et al. Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but 253 
distinct kinetics to CD28 and CTLA-4 receptors. Immunity. 1, 793-801 (1994). 254 
15. Stegh, A.H. et al. Bcl2L12 inhibits post-mitochondrial apoptosis signaling in glioblastoma. 255 
Genes Dev. 21, 98-111 (2007). 256 
16. Sun, J. et al. A cytosolic granzyme B inhibitor related to the viral apoptotic regulator cytokine 257 
response modifier A is present in cytotoxic lymphocytes. J. Biol. Chem. 271, 27802-27809 258 
(1996). 259 
17. Pan, F. et al. Eos mediates Foxp3-dependent gene silencing in CD4+ regulatory T cells. 260 
Science 325, 1142-1146 (2009). 261 
18. Akiyama, T., Shinzawa, M., & Akiyama, N. RANKL-RANK interaction in immune regulatory 262 
systems. World J. Orthop. 3, 142-150 (2012). 263 
19. Ollmann, M.M., Lamoreux, M.L., Wilson, B.D. & Barsh, G.S. Interaction of Agouti protein 264 
with the melanocortin 1 receptor in vitro and in vivo. Genes Dev. 12, 316-330 (1998). 265 
20. Praetorius, C. et al. A polymorphism in IRF4 affects human pigmentation through a 266 
tyrosinase-dependent MITF/TFAP2A pathway. Cell 155, 1022-1033 (2013). 267 
21. Jin, Y. et al. Next-generation DNA re-sequencing identifies common variants of TYR and 268 
HLA-A that modulate the risk of generalized vitiligo via antigen presentation. J. Invest. 269 
Dermatol. 132, 1730-1733 (2012). 270 
22. Gualco, G., Weiss, L.M. & Bacchi, C.E. MUM1/IRF4. A review. Appl. Imunohistochem. Mol. 271 
Morphol. 18, 301-310 (2010). 272 
23. Visser, M., Palstra, R.J. & Kayser, M. Allele-specific transcriptional regulation of IRF4 in 273 
melanocytes is mediated by chromatin looping of the intronic rs12203592 enhancer to the 274 
IRF4 promoter. Hum. Mol. Genet. 25, 2629-2661 (2015). 275 
12 
 
24. Nan H. et al. Genome-wide association study of tanning phenotype in a population of 276 
European ancestry. J. Invest. Dermatol. 129, 2250-2257 (2009). 277 
25. Shoag, J. et al. PGC-1 coactivators regulate MITF and the tanning response. Mol. Cell 49, 278 
145-157. (2013). 279 
26. Read, J., Wadt, K.A. & Hayward, N.K. Melanoma genetics. J. Med. Genet. 53, 1-14 (2016).  280 
27. Spritz, R.A. The genetics of generalized vitiligo: autoimmune pathways and an inverse 281 
relationship with malignant melanoma. Genome Med. 19, 2:78 (2010). 282 
28. Das, P.K., van den Wijngaard R.M.J.G.J., Wankowicz-Kalinska, A. & Le Poole, I.C. A 283 
symbiotic concept of autoimmunity and tumour immunity: lessons from vitiligo. Trends 284 
Immunol. 22, 130-136 (2001). 285 
29. Teulings, H.E. et al. Decreased risk of melanoma and nonmelanoma skin cancer in patients 286 
with vitiligo: a survey among 1307 patients and their partners. Br. J. Dermatol. 168, 162-171 287 
(2013). 288 
30. Paradisi, A. et al. Markedly reduced incidence of melanoma and nonmelanoma skin cancer 289 
in a nonconcurrent cohort of 10040 patients with vitiligo. J. Am. Acad. Dermatol. 71, 1110-290 
1116 (2014). 291 
31. Teulings, H.E. et al. Vitiligo-like depigmentation in patients with stage III-IV melanoma 292 
receiving immunotherapy and its association with survival: a systematic review and meta-293 
analysis. J. Clin Onc. 33, 773-781 (2015).   294 
32. Laberge, G. et al. Early disease onset and increased risk of other autoimmune diseases in 295 
familial generalized vitiligo. Pigment Cell Res. 18, 300-305 (2005). 296 
33. Dubois, P.C. et al. Multiple common variants for celiac disease influencing immune gene 297 
expression. Nat. Genet. 42, 295-302 (2010). 298 
34. Franke A. et al. Genome-wide meta-analysis increases to 71 the number of confirmed 299 
Crohn's disease susceptibility loci. Nat. Genet. 42, 1118-1125 (2010). 300 
13 
 
35. Juyal, G. et al. Genome-wide association scan in north Indians reveals three novel HLA-301 
independent risk loci for ulcerative colitis. Gut 64, 571-579 (2015). 302 
36. Melum E. et al. Genome-wide association analysis in primary sclerosing cholangitis 303 
identifies two non-HLA susceptibility loci. Nat. Genet. 43, 17-19 (2011). 304 
37. Petukhova, L. et al. Genome-wide association study in alopecia areata implicates both 305 
innate and adaptive immunity. Nature 466, 113-117 (2010). 306 
38. Gregersen, P.K. et al. REL, encoding a member of the NF-kappaB family of transcription 307 
factors, is a newly defined risk locus for rheumatoid arthritis. Nat. Genet. 41, 820-823 308 
(2009). 309 
39. Chu, X. et al. A genome-wide association study identifies two new risk loci for Graves' 310 
disease. Nat. Genet. 43, 897-901 (2011). 311 
40. Eriksson, N. et al. Novel associations for hypothyroidism include known autoimmune risk 312 
loci. PloS One 7, e34442 (2012). 313 
41. Renton, A.E. et al. A genome-wide association study of myasthenia gravis. JAMA Neurol. 314 
72, 396-404 (2015). 315 
42. Plagnol, V. et al. Genome-wide association analysis of autoantibody positivity in type 1 316 
diabetes cases. PLoS Genet. 7, e1002216 (2011). 317 
43. Yang, W. et al. Meta-analysis followed by replication identifies loci in or near CDKN1B, 318 
TET3, CD80, DRAM1, and ARID5B as associated with systemic lupus erythematosus in 319 
Asians. Am. J. Hum. Genet. 92, 41-51 (2013). 320 
44. Hou, S. et al. Identification of a susceptibility locus in STAT4 for Behcet's disease in Han 321 
Chinese in a genome-wide association study. Arth. Rheumat. 64, 4104-4113 (2012). 322 
45. Li, Y. et al. A genome-wide association study in Han Chinese identifies a susceptibility locus 323 
for primary Sjogren's syndrome at 7q11.23. Nat. Genet. 45, 1361-1365 (2013). 324 
14 
 
46. Lee, Y.H., Bae, S.C., Choi, S.J., Ji, J.D. & Song, G.G. Genome-wide pathway analysis of 325 
genome-wide association studies on systemic lupus erythematosus and rheumatoid arthritis. 326 
Molec. Biol. Rep. 39, 10627-10635 (2012). 327 
47. Han, J.W. et al. Genome-wide association study in a Chinese Han population identifies nine 328 
new susceptibility loci for systemic lupus erythematosus. Nat. Genet. 41, 1234-1237 (2009). 329 
48. Corradin, O. & Schcheri, P.C. Enhancer variants: evaluating functions in common disease. 330 
Genome Med. 6, 85 (2014). 331 
49. Gusev, A. et al. Partitioning heritability of regulatory and cell-type-specific variants across 11 332 
common diseases. Am. J. Hum. Genet. 95, 535-552 (2014). 333 
50. Paul, D.S. et al. Functional interpretation of non-coding sequence variation: concepts and 334 
challenges. Bioessays 36, 191-199 (2014). 335 
51. Finucane, H.K. et al. Partitioning heritability by functional annotation using genome-wide 336 
association summary statistics. Nat. Genet. 47, 1228-1235 (2015). 337 
52. Nicolae, D. et al. Trait-associated SNPs are more likely to be eQTLs: annotation to enhance 338 
discovery from GWAS. PLoS Genet. 6, e1000888 (2010). 339 
53. Ferrara, T.M., Jin, Y., Gowan, K., Fain, P.R., & Spritz, R.A. Risk of generalized vitiligo is 340 
associated with the common 55R-94A-247H variant haplotype of GZMB (encoding 341 
Granzyme B). J. Investig. Dermatol. 133, 1677-1679 (2013). 342 
54. Hayashi, M. et al. Autoimmune vitiligo is associated with gain of function by a transcriptional 343 
regulator that elevates expression of HLA-A*02:01 in vivo. Proc. Natl. Acad. Sci. U.S.A. 113, 344 
1357-1362 (2016). 345 
55. Cavalli, G. et al. MHC class II super-enhancer increases surface expression of HLA-DR and 346 
HLA-DQ and affects cytokine production in autoimmune vitiligo. Proc. Natl. Acad. Sci. U.S.A. 347 
113, 1363-1368 (2016). 348 
56. Shlyueva, D., Stampfel, G. & Stark, A. Transcriptional enhancers from properties to 349 
genome-wide predictions. Nat. Rev. Genet. 15, 272-286 (2014). 350 
15 
 
57. Kellis, M. et al. Defining functional DNA elements in the human genome. Proc. Natl. Acad. 351 
Sci. U.S.A. 111, 6131–6138 (2014). 352 
58. Gamazon, E.R. et al. A gene-based association method for mapping traits using reference 353 
transcriptome data. Nat. Genet. 47, 1091-1098 (2015). 354 
 355 
  356 
16 
 
Figure Legends (Main text) 357 
 358 
Figure 1 Genome-wide meta-analysis results. The genome-wide distribution of –log10 (P values) 359 
from the Cochran-Mantel-Haenszel meta-analysis for 8,966,411 genotyped and imputed 360 
markers from GWAS1, GWAS2, and GWAS3 is shown across the chromosomes. The dotted 361 
line indicates the threshold for genome-wide significance (P < 5 x 10-8). 362 
 363 
Figure 2 Bioinformatic functional interaction network analysis of proteins encoded by all 364 
positional candidate genes at all confirmed and suggestive vitiligo candidate loci. As a first step, 365 
unsupervised functional interaction network analysis was carried out using STRING v10.011, 366 
considering each protein as a node and permitting < 5 second-order interactions to maximize 367 
connectivity. Nodes that shared no edges with other nodes were then excluded from the 368 
network. Edge colors are per STRING: teal, interactions from curated databases; purple, 369 
experimentally determined interactions; green, gene neighborhood; blue, databases; red, gene 370 
fusions; dark blue, gene co-occurrence; pale green, text-mining; black, co-expression; lavender, 371 
protein homology. Note that SMEK2 is an alternative name for PPP4R3B. 372 
 373 
Figure 3 Concordant associations for vitiligo and other autoimmune and inflammatory diseases. 374 
We searched the NHGRI-EBI GWAS Catalog and PubMed for associations of the 48 genome-375 
wide significant and 7 suggestive vitiligo susceptibility loci with other autoimmune, inflammatory, 376 
and immune-related disorders, and for association with normal human pigmentation variation. 377 
Only reported associations that achieved genome-wide significance (P < 5 x 10-8) are included. 378 
RA, rheumatoid arthritis; T1D, type 1 diabetes mellitus; AITD, autoimmune thyroid disease; 379 
SLE, systemic lupus erythematosus; IBD, inflammatory bowel disease; MS, multiple sclerosis; 380 
MG, myasthenia gravis; AI hepatitis, autoimmune hepatitis.  381 
 382 
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Figure 4 Enrichment estimates for functional annotations. The combined CMH GWAS123 383 
summary statistics were analyzed using the stratified LD score regression method utilizing the 384 
full baseline model51. Regulatory, yellow; protein coding, blue; intron, green. Bar height 385 
represents enrichment which is defined to be the proportion of SNP heritability in the category 386 
divided by the proportion of SNPs in that category. Error bars represent jackknife standard error 387 
around the enrichment. For each category, percentage of the total markers in the category is in 388 
parentheses. Dashed line represents a ratio of 1 (no enrichment). Asterisks indicate enrichment 389 
significant at P < 0.05 after Bonferroni correction for the 20 categories tested (the categories 390 
conserved, repressed, transcribed, and promoter flanking were removed and considered 391 
insufficiently specific). CTCF, CCCTC-binding factor; DGF, digital genomic footprint; DHS, 392 
DNase hypersensitivity site; TFBS, transcription factor binding site; TSS, transcriptional start 393 
site; 5’ and 3’ UTR, 5’ and 3’ untranslated regions. H3K4me1, H3K4me3, H3K9ac, and 394 
H3K27ac are regulatory chromatin marks56,57. 395 
 396 
  397 
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Table 1  Allelic associations at vitiligo susceptibility loci following GWAS meta-analysis and replication study 
      GWAS123  meta-analysis  GWAS3 replication study  GWAS123 &  GWAS3 replication study meta-analysis  
Chr. Variant Position (Build 37) Locus EA/OA  P value 
Odds      
ratio  P value 
Odds      
ratio  P value 
Odds ratio    
(95% CI) 
Heritability 
explained* 
(%) 
1 rs301807 8484823 RERE A/G  1.84 x 10-12 1.22  4.09 x 10-04 1.17  4.14 x 10-15  1.21 (1.15-1.27) 0.003 
1 rs2476601 114377568 PTPN22 A/G  2.21 x 10-14 1.39  1.08 x 10-05 1.36  1.21 x 10-18 1.38 (1.29-1.49)  0.003 
1 rs78037977 172715702 FASLG G/A  1.39 x 10-13 1.33  8.95 x 10-05 1.29  6.74 x 10-17 1.32 (1.24-1.41)  0.003 
1 rs16843742 198672299 PTPRC C/T  8.84 x 10-09 0.82  1.87 x 10-02 0.88  1.02 x 10-09 0.83 (0.79-0.88)  0.002 
2 rs10200159 55845109 PPP4R3B C/T  3.35 x 10-13 1.48  3.70 x 10-07 1.55  3.73 x 10-19 1.51 (1.38-1.66)  0.003 
2 rs4308124 112010486 BCL2L11-MIR4435-2HG C/T  4.99 x 10-08 1.17  1.67 x 10-02 1.12  3.96 x 10-09 1.15 (1.10-1.21)  0.002 
2 rs2111485 163110536 IFIH1 A/G  2.69 x 10-22 0.75  8.58 x 10-05 0.83  6.40 x 10-25 0.77 (0.73-0.81)  0.008 
2 rs231725 204740675 CTLA4 A/G  2.25 x 10-08 1.18  1.57 x 10-03 1.16  1.49 x 10-10 1.18 (1.12-1.24)  0.002 
2 rs41342147 242407588 FARP2-STK25 A/G  8.03 x 10-07 0.80  1.25 x 10-03 0.80  3.70 x 10-09 0.80 (0.74-0.86)  0.003 
3 rs35161626 23512312 UBE2E2 I/D  7.34 x 10-07 0.87  1.09 x 10-02 0.89  3.13 x 10-08 0.87 (0.83-0.92)  0.001 
3 rs34346645 71557945 FOXP1 A/C  6.11 x 10-14 0.80  4.23 x 10-06 0.81  7.99 x 10-19 0.80 (0.76-0.84)  0.004 
3 rs148136154 119283468 CD80-ADPRH C/T  5.02 x 10-15 1.37  1.74 x 10-02 1.17  4.58 x 10-15 1.31 (1.22-1.40)  0.003 
3 rs13076312 188089254 LPP T/C  3.58 x 10-22 1.32  3.48 x 10-10 1.33  1.61 x 10-30 1.32 (1.26-1.38)  0.009 
3 rs6583331 196347253 FBXO45-NRROS A/T  1.39 x 10-07 0.86  3.62 x 10-02 0.91  2.53 x 10-08 0.87 (0.83-0.92)  0.002 
4 rs1031034 102223386 PPP3CA A/C  4.78 x 10-06 0.86  2.14 x 10-03 0.86  3.43 x 10-08 0.86 (0.81-0.91)  0.001 
6 rs12203592 396321 IRF4 T/C  1.03 x 10-09 0.77  3.17 x 10-08 0.68  8.86 x 10-16 0.75 (0.70-0.80)  0.001 
6 rs78521699 2908591 SERPINB9 G/A  3.33 x 10-06 0.79  2.27 x 10-03 0.80  2.54 x 10-08 0.79 (0.73-0.86)  0.001 
6 rs60131261 29937335 HLA-A D/I  2.63 x 10-48 1.53  8.01 x 10-20 1.54  1.56 x 10-66 1.54 (1.46-1.61)  0.016 
6 rs9271597 32591291 HLA-DRB1/DQA1 A/T  3.15 x 10-89 1.77  nd nd  nd nd  0.042 
6 rs72928038 90976768 BACH2 A/G  1.12 x 10-11 1.28  2.04 x 10-04 1.25  1.00 x 10-14 1.27 (1.19-1.35)  0.003 
6 rs2247314 167370230 RNASET2-FGFR1OP-CCR6 C/T  1.97 x 10
-13 0.79  1.56 x 10-06 0.79  1.72 x 10-18 0.79 (0.75-0.84)  0.003 
7 rs117744081 29132279 CPVL G/A  3.74 x 10-22 1.95  1.88 x 10-06 1.66  8.72 x 10-26 1.84 (1.64-2.06)  0.004 
8 rs2687812 133931055 TG-SLA-WISP1 A/T  1.98 x 10-11 1.21  1.69 x 10-03 1.15  2.19 x 10-13 1.19 (1.14-1.25)  0.007 
9 rs10986311 127071493 NEK6 C/T  5.45 x 10-07 1.16  5.10 x 10-03 1.14  1.01 x 10-08 1.15 (1.10-1.21)  0.001 
10 rs706779 6098824 IL2RA C/T  1.30 x 10-24 0.74  9.25 x 10-05 0.84  7.20 x 10-27 0.77 (0.73-0.81)  0.012 
10 rs71508903 63779871 ARID5B T/C  1.09 x 10-06 1.18  1.52 x 10-03 1.19  6.93 x 10-09 1.18 (1.12-1.25)  0.001 
10 rs12771452 115488331 CASP7 A/G  9.16 x 10-08 0.83  8.42 x 10-06 0.79  4.43 x 10-12 0.82 (0.78-0.87)  0.002 
11 rs1043101 35274829 CD44-SLC1A2 G/A  2.08 x 10-13 1.24  4.20 x 10-06 1.24  5.26 x 10-18 1.23 (1.18-1.29)  0.003 
11 rs12421615 64021605 PPP1R14B-PLCB3-BAD- A/G  3.38 x 10-06 0.87  3.78 x 10-03 0.87  4.81 x 10-08 0.87 (0.83-0.91)  0.001 
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  399 
GPR137-KCNK4-TEX40-
ESRRA-TRMT112-
PRDX5 
11 rs1126809 89017961 TYR A/G  7.13 x 10-32 0.67  2.54 x 10-13 0.68  1.16 x 10-43 0.67 (0.63-0.71)  0.012 
11 rs11021232 95320808 Gene desert C/T  1.01 x 10-21 1.38  3.81 x 10-04 1.22  2.10 x 10-23 1.34 (1.26-1.41)  0.005 
12 rs2017445 56407072 IKZF4 A/G  3.81 x 10-20 1.31  1.22 x 10-12 1.40  6.62 x 10-31 1.33 (1.27-1.40)  0.005 
12 rs10774624 111833788 SH2B3-ATXN2 A/G  1.88 x 10-14 0.80  1.52 x 10-10 0.75  6.22 x 10-23 0.79 (0.75-0.83)  0.004 
13 rs35860234 43070206 TNFSF11 G/T  2.82 x 10-06 1.16  3.45 x 10-04 1.20  4.76 x 10-09 1.17 (1.11-1.23)  0.001 
14 rs8192917 25102160 GZMB C/T  1.37 x 10-10 1.23  1.23 x 10-06 1.29  8.91 x 10-16 1.25 (1.18-1.32)  0.002 
15 rs1635168 28535266 OCA2-HERC2 A/C  6.97 x 10-13 1.43  7.45 x 10-03 1.25  8.78 x 10-14 1.37 (1.26-1.49)  0.003 
16 rs4268748 90026512 MC1R? C/T  1.63 x 10-20 0.73  8.23 x 10-15 0.66  2.88 x 10-33 0.71 (0.67-0.75)  0.013 
17 rs11079035 40289012 KAT2A-HSPB9-RAB5C A/G  3.20 x 10-06 1.18  3.19 x 10-05 1.28  6.77 x 10-10 1.21 (1.14-1.29)  0.001 
18 rs8083511 60028655 TNFRSF11A C/A  9.42 x 10-10 1.24  3.23 x 10-02 1.13  2.81 x 10-10 1.21 (1.14-1.28)  0.002 
19 rs4807000 4831878 TICAM1 A/G  1.58 x 10-09 1.19  2.11 x 10-06 1.24  1.94 x 10-14 1.21 (1.15-1.26)  0.002 
19 rs2304206 50168871 SCAF1-IRF3-BCL2L12 A/G  6.45 x 10-09 0.82  4.52 x 10-02 0.90  2.36 x 10-09 0.84 (0.80-0.89)  0.002 
20 rs6059655 32665748 RALY-EIF252-ASIP-AHCY-ITCH A/G  3.58 x 10
-13 0.63  3.08 x 10-08 0.57  1.04 x 10-19 0.61 (0.55-0.68)  0.004 
20 rs6012953 49123043 PTPN1 G/A  1.18 x 10-07 1.16  1.74 x 10-02 1.11  9.47 x 10-09 1.15 (1.10-1.20)  0.002 
21 rs12482904 43851828 UBASH3A A/T  5.74 x 10-29 1.43  1.16 x 10-03 1.18  5.84 x 10-29 1.35 (1.28-1.43)  0.010 
22 rs229527 37581485 C1QTNF6 A/C  1.40 x 10-24 1.34  1.15 x 10-07 1.27  1.14 x 10-30 1.32 (1.26-1.38)  0.006 
22 rs9611565 41767486 ZC3H7B-TEF C/T  1.99 x 10-12 0.78  3.34 x 10-04 0.82  3.13 x 10-15 0.79 (0.75-0.84)  0.003 
x rs73456411 29737404 IL1RAPL1 T/G  1.57 x 10-07 1.72  5.90 x 10-03 1.62  7.34 x 10-10 1.77 (1.47-2.13)  0.001 
x rs5952553 49392721 CCDC22-FOXP3-GAGE C/T  1.81 x 10-08 0.85  3.48 x 10-02 0.92  1.05 x 10-09 0.86 (0.82-0.90)  0.001 
*Heritability explained by all independent signals of the locus. Chr., chromosome; CI, confidence interval; nd, not determined; EA, effect allele; OA, other allele. Bold, novel significant vitiligo susceptibility loci. 
The chromosome 16 association peak spans a large number of genes, including MC1R. 
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ONLINE METHODS 400 
 401 
 402 
Subjects 403 
The genome-wide portion of this study included unrelated cases from our three generalized 404 
vitiligo GWAS: GWAS14 (n = 1514), GWAS26 (n = 450), and the current GWAS3 (n = 1090). All 405 
cases were of non-Hispanic-Latino European-derived white ancestry (EUR) from North America 406 
and Europe, and met strict clinical criteria for generalized vitiligo59. All controls were EUR 407 
individuals not specifically known to have any autoimmune disease or malignant melanoma, for 408 
whom genome-wide genotypes were obtained from the NCBI database of Genotypes and 409 
Phenotypes (dbGaP; phs000092.v1.p1, phs000125.v1.p1, phs000138.v2.p1, phs000142.v1.p1, 410 
phs000168.v1.p1, phs000169.v1.p1, phs000206.v3.p2, phs000237.v1.p1, phs000346.v1.p1, 411 
and phs000439.v1.p1 for GWAS1; phs000203.v1.p1, and phs000289.v2.p1 for GWAS2; 412 
phs000196.v2.p1, phs000303.v1.p1, phs000304.v1.p1, phs000368.v1.p1, phs000381.v1.p1, 413 
phs000387.v1.p1, phs000389.v1.p1, phs000395.v1.p1, phs000408.v1.p1, phs000421.v1.p1, 414 
phs000494.v1.p1, and phs000524.v1.p1 for GWAS3). Control datasets were matched to each of 415 
the three GWAS case datasets based on platforms used for genotyping. The independent 416 
replication study included 1827 unrelated EUR vitiligo cases and 2181 unrelated EUR controls 417 
not included in any of the GWAS. All subjects provided written informed consent. This study was 418 
carried out under the jurisdiction of each local IRB with overall oversight of the Colorado Multiple 419 
Institutional Review Board (COMIRB). 420 
 421 
Genome-wide genotyping 422 
Saliva specimens were obtained using a DNA self-collection kit (Oragene, DNA Genotek), and 423 
DNA was prepared using either the Maxwell apparatus/16 LEV Blood DNA kit (Promega) or 424 
the DNA Genotek Oragene Purifier protocol. DNA concentrations were measured using either 425 
the Qubit dsDNA BR Assay kit and Qubit 2.0 Fluorometer (Invitrogen) or the Promega 426 
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QuantiFluor ONE dsDNA kit and GloMax®-Multi+ Detection System (Promega). 427 
Genome-wide genotyping for the GWAS3 cases was performed for 716,503 variants 428 
using Illumina Human OmniExpress BeadChips by the Center for Inherited Disease Research 429 
(CIDR). Genotype data for GWAS3 were deposited in dbGaP (phs000224.v3.p1). GWAS14 430 
and GWAS26 have been described previously. 431 
 432 
Genome-wide quality control procedures 433 
Quality control filtering of genome-wide genotype data was carried out using PLINK60, version 434 
1.9. For each case/control dataset, DNA strand calls were reversed as needed. Cases were 435 
excluded on the basis of SNP call rates <98.5%, discordance between reported and observed 436 
sex, or inadvertent subject duplication, and controls were excluded on the basis of SNP call 437 
rates < 98%. SNPs were excluded on the basis of genotype missing rate > 2% for SNPs with 438 
observed minor allele frequency (MAF) > 0.01, and for SNPs with MAF < 0.01 exclusion 439 
criteria were genotype missing rate >1% and < 5 minor alleles observed, or significant (P < 440 
10−4) deviation from Hardy-Weinberg equilibrium. For X chromosome SNPs, Hardy-Weinberg 441 
equilibrium tests were performed in females, and SNPs with P < 10−4 were excluded from the 442 
final analysis. For each GWAS, only SNPs that existed in all case and control datasets were 443 
retained for imputation. 444 
Within each GWAS, subjects were excluded based on cryptic relatedness identified by 445 
pairwise identity-by-descent estimations (pi-hat > 0.0625), in which case the individual with 446 
lower SNP call rate was excluded. For each of the three GWAS, the cleaned case dataset was 447 
combined with one cleaned control dataset at a time and the genotype data of 270 subjects of 448 
Phase I and II of the International HapMap Project from 4 populations, and principal 449 
components analysis (PCA) was performed with EIGENSOFT59 based on tag-SNPs (within 450 
which no pair were correlated with r2 >0.2) selected from genotyped SNPs. The first two 451 
eigenvectors were used to produce a PCA plot. A PCA plot was first made for cases and 452 
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HapMap samples, and cases that were clearly separated from the main cluster of cases and 453 
HapMap EUR samples were excluded as outliers. A PCA plot of controls and HapMap 454 
samples was then made, and the same x and y coordinates that separated the case outliers 455 
from the main cluster of cases and HapMap EUR samples were used to identify control 456 
outliers. 457 
After all QC procedures, the final number of genotyped SNPs remaining in GWAS1, 458 
GWAS2, and GWAS3 were 464,902, 494,043, and 483,609, respectively. For autosomal 459 
analyses, the final numbers of cases and controls in GWAS1, GWAS2, and GWAS3 were 460 
1,381 and 14,518, 413 and 5,209, and 1,059 and 17,678, respectively, whereas for X 461 
chromosome analyses, the final numbers of cases and controls in GWAS1, GWAS2, and 462 
GWAS3 were 1,380 and 9,439, 413 and 5,209, and 1,059 and 14,220, respectively. This 463 
sample size provided at least 85% power to detect associations with OR > 1.22 at genome-464 
wide significance (P = 5 x 10-8) for MAF > 0.25. 465 
 466 
Genome-wide Genotype Imputation 467 
For each GWAS, we used SHAPEIT version2 to pre-phase genotypes to produce best-guess 468 
haplotypes, and then performed imputation with these estimated haplotypes using IMPUTE2 469 
and the 1000 Genomes Project phase I integrated variant set version 3 (March, 2012) as the 470 
reference panel. All cryptic related individuals and outliers from each GWAS were included in 471 
the process to improve imputation accuracy, but were removed for the final analyses. Only 472 
genotypes with imputation INFO > 0.5 were retained, which were combined with prior SNP 473 
genotype data. Imputed genotypes for variants with MAF > 0.01 calculated from all 3 GWAS 474 
combined and without significant (P > 10−5) deviation from Hardy-Weinberg equilibrium were 475 
used in the final analysis, which included 8,721,242 autosome variants and 245,169 476 
chromosome X variants. 477 
 478 
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Replication study genotyping and quality control procedures 479 
For the replication study, genotyping was attempted for 379 variants using a custom Illumina 480 
GoldenGate array by CIDR. 71 SNPs were excluded on the basis of genotype missing rate > 2% 481 
(which includes apparent technical failures), or significant (P < 10−4) deviation from Hardy-482 
Weinberg equilibrium. For X chromosome SNPs, Hardy-Weinberg equilibrium tests were 483 
performed in females. Subjects were excluded on the basis of SNP call rates <95%, or 484 
discordance between reported and observed sex. Unintended duplicate samples were identified 485 
by pairwise identity-by-descent estimations (pi-hat > 0.99), in which case the individual with 486 
lower SNP call rate was excluded. The final numbers of remaining cases and controls were 487 
1,827 and 2,181, respectively, providing at least 80% power to replicate associations at P = 0.05 488 
with Bonferroni correction for up to 48 independent tests for OR ≥ 1.23 for MAF ≥ 0.25. 489 
 490 
Statistical analyses 491 
To control for the effects of population stratification, we assigned cases and controls of each 492 
GWAS to homogenous clusters using GemTools60, and performed Cochran-Mantel- Haenszel 493 
(CMH) analysis to test for association for each GWAS and the combined GWAS data, with the 494 
cluster variable defined by the case-control clusters from each GWAS. After removing variants 495 
within the extended MHC, the genomic inflation factor for GWAS1, GWAS2, and GWAS3 was 496 
1.068, 1.059, and 1.013, respectively. For the combined GWAS1-GWAS2-GWAS3 genotype 497 
data for shared SNPs, the genomic inflation factor was 1.019. 498 
For the replication study, after quality control procedures we compared allele 499 
frequencies for the remaining 308 SNPs in the remaining 1,827 cases and 2,181 controls using 500 
the Cochran-Armitage trend test. ORs and 95% confidence limits were calculated by logistic 501 
regression analysis. We used CMH analysis to obtain ORs and P values for the combined 502 
GWAS plus the replication study data, with the cluster variable defined by the case-control 503 
clusters from each GWAS and the replication study data as one cluster. To analyze X 504 
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chromosome SNPs, we assumed complete X-inactivation and similar effect size between 505 
males and females, with the effect of having an A allele in a male equal to the effect of having 506 
two A alleles in a female63. We thus coded males as homozygous for the allele carried for each 507 
variant and tested for association by CMH analysis to obtain ORs and P values for each 508 
GWAS, the combined GWAS, and the combined GWAS plus the replication study data, and by 509 
the Cochran- Armitage trend test for the replication study data.  510 
To test heterogeneity of associations across the three GWAS and the replication study 511 
data, we performed the Cochran Q test. The analysis was done with PLINK, version 1.07, 512 
using the ORs and standard errors estimated from the CMH analysis of each GWAS, and from 513 
logistic regression analysis of the replication study data. The I2 statistic from the Q test 514 
quantifies heterogeneity and ranges from 0% to 100%64, with a value of 75% or greater 515 
typically taken to indicate a high degree of heterogeneity65. 516 
To test for multiple independent signals at each locus, we performed logistic regression 517 
analysis of each locus conditional on the most significantly associated variant, including as 518 
covariates in the model the significant principal components for each GWAS derived from 519 
GemTools62 to control for population stratification, and used a stepwise procedure to select 520 
additional variants, one by one, until no additional variants showed conditional P values < 1.0 x 521 
10-5. If a tested variant and the conditional variant could not improve each other significantly (P 522 
> 0.05 when comparing the two SNP model to a single SNP model), then both variants were 523 
considered to represent the same signal. We calculated the variance explained by a specific 524 
variant or a set of variants from the combined GWAS as the Pseudo R2 of a logistic regression 525 
model which included the specific variants tested. 526 
 527 
Bioinformatic pathway and functional enrichment analyses 528 
To screen for functional relationships among the vitiligo candidate genes, we carried out 529 
pathway analysis of the protein products of all positional candidate genes at all 48 confirmed 530 
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loci and the seven suggestive loci using g:PROFILER10, PANTHER11, and STRING12. To 531 
assess enrichment of association signals in different functional genomic categories contributing 532 
to vitiligo heritability, we applied stratified LD score regression51 to the combined CMH 533 
GWAS123 summary statistics. The regression model contained 24 overlapping functional 534 
categories, including coding, UTR, promoter and intronic regions, annotations for different 535 
histone marks, DNase I hypersensitivity site (DHS) regions, combined ChromHMM and Segway 536 
predictions, conserved regions in mammals, super-enhancers and FANTOM5 enhancers. For 537 
each of the 24 categories, a 500-bp window was used. Linkage disequilibrium data were 538 
provided by the LD score software, estimated from the EUR samples in the 1000 Genomes 539 
Project Phase 1. Enrichment per category was calculated by the ratio of the estimated 540 
proportion of heritability explained by the category over the proportion of the markers in the 541 
category. 542 
 543 
PrediXcan and Monocyte eQTL Co-Localization analyses 544 
We carried out a gene-based test of association of vitiligo with “imputed” expression profiles for 545 
11,553 autosomal genes in whole blood using PrediXcan58. The analysis included 2,853 cases 546 
and 37,412 controls from the combined GWAS. Association testing between expression 547 
estimates for each gene and affection status for vitiligo was performed by generalized logistic 548 
regression. P values were adjusted for the number of genes tested (n = 11,553). NRROS, 549 
ZC3H7B, TNFRSF11A, BCL2L12, RALY, ASIP, OCA2, and TYR were excluded from the 550 
PrediXcan analysis due to poor prediction of gene expression in blood cells. 551 
We derived expression quantitative trait loci (eQTLs) in peripheral blood monocytes from 552 
414 EUR subjects with paired genotyping and gene expression data66. SHAPEIT version2 was 553 
used to pre-phase genotypes to produce best-guess haplotypes with imputation performed 554 
using IMPUTE2 and the 1000 Genomes Project phase I integrated variant set version 3 (March, 555 
2012) as reference panel. We tested for co-localization of eQTL and vitiligo GWAS autosomal 556 
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association patterns as described67,68. Vitiligo susceptibility loci were defined by windows of 557 
robust association plus an added 100 kb buffer on both sides. eQTL probes were selected by 558 
choosing probes that resided within these windows. Probe quality annotation was performed 559 
using ReMOAT69 and all probes with an annotation of “bad” were removed. After removing non-560 
autosomal loci and duplicate probe IDs, a total of 904 probes remained. All vitiligo susceptibility 561 
loci contained at least one probe with the exception of the gene desert 3’ of TYR, for which the 562 
only probe that intersected the locus was excluded due to ReMOAT annotation of “bad”. Within 563 
each locus window, all SNPs were tested for association with all probes using linear regression. 564 
P values, MAF for each SNP and respective sample sizes were used as input to test for co- 565 
localization, simultaneously testing five mutually exclusive hypotheses by generating 5 566 
corresponding posterior probabilities (PP): 567 
• H0 (PP0): There is no association with either the GWAS or the eQTL. 568 
• H1 (PP1): There is association for the GWAS only. 569 
• H2 (PP2): There is association for the eQTL only. 570 
• H3 (PP3): There is association for both the GWAS and the eQTL, but the associated 571 
variants are different for the GWAS and the eQTL. 572 
• H4 (PP4): The associated variants are the same for both the GWAS and the eQTL (co- 573 
localization). 574 
Posterior probabilities were calculated using the R package “coloc” using default settings for 575 
prior probabilities of association. Co-localization was assessed as per Guo et al.68; significant 576 
co-localization was PP3+PP4 > 0.99 and PP4:PP3 > 5, and suggestive co-localization was 577 
PP3+PP4 > 0.95 and PP4:PP3 > 3.  578 
 579 
URLs. 1000 Genomes Project, http://www.1000genomes.org/; coloc, https://cran.r- 580 
project.org/web/packages/coloc/index.html; GemTools, 581 
http://wpicr.wpic.pitt.edu/WPICCompgen/GemTools/GemTools.htm;  IMPUTE2, 582 
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https://mathgen.stats.ox.ac.uk/impute/impute_v2.html; International HapMap Project, 583 
http://hapmap.ncbi.nlm.nih.gov/; PrediXcan, https://github.com/hriordan/PrediXcan; SHAPEIT, 584 
http://www.shapeit.fr/; REMOAT, http://remoat.sysbiol.cam.ac.uk/transcript.php. 585 
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